7,541.40

-38.67

-0.51%

51,983.98

+213.67

+0.41%

25,164.32

-272.68

-1.07%

2,805.88

-5.97

-0.21%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,956.60

+57.70

+1.48%

76,718.53

-985.55

-1.27%

Crude Oil Dec 26

96.32

-7.80

-7.49%

US Private Equity

10,850.63

-82.20

-0.75%

LIVE It’s John Ternus’ first earnings call as Apple CEO. Listen in here.

Iceland - Delayed Quote ISK

Oculis Holding AG (OCS.IC)

994.00 -44.75 (-4.31%)

At close: 3:23:45 PM GMT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks 8h ago

OCS

EYPT
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)

Zacks 1mo ago

OCS
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

Zacks 1mo ago

HALO

OCS
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade

Zacks 2mo ago

OCS
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

Zacks 2mo ago

OCS
Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor

PREMIUM
MT Newswires 2mo ago

OCS
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Zacks 2mo ago

OCS
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

Motley Fool 4mo ago

OCS

^GSPC

EVMN
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals

MarketBeat 5mo ago

OCS
OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target

Stocktwits 5mo ago

OCS
Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint

PREMIUM
MT Newswires 5mo ago

OCS
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Zacks 5mo ago

OCS

Performance Overview

Return	OCS.IC	S&P 500 (^GSPC)
YTD	-61.32%	+10.35%
1-Year	-59.92%	+10.43%
3-Year	-41.18%	+74.95%

Mobilize your Website

View Site in Mobile | Classic

Share by: